[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019; 69: 7-34.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians. 2016; 66: 115-32.
[3] Li L, Gao Q, Xu G, et al. Postoperative recurrence analysis of breast cancer patients based on clinical serum markers using discriminant methods. CANCER BIOMARK. 2017; 19: 403-9.
[4] Ma R, Feng Y, Lin S, et al. Mechanisms involved in breast cancer liver metastasis. J TRANSL MED. 2015; 13.
[5] Zhong C, Chen F, Yang J, et al. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. ACTA PHARMACOL SIN. 2018; 39: 1048-63.
[6] Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. GENE. 2018; 654: 77-86.
[7] Mross K, Frost A, Steinbild S, et al. A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. CLIN CANCER RES. 2012; 18: 2658-67.
[8] Strumberg D, Richly H, Hilger RA, et al. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors. J CLIN ONCOL. 2005; 23: 965-72.
[9] Huang L, Huang Z, Bai Z, Xie R, Sun L, Lin K. Development and strategies of VEGFR-2/KDR inhibitors. FUTURE MED CHEM. 2012; 4: 1839-52.
[10] Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. BIOCHEM J. 2011; 437: 199-213.
[11] Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. NAT REV CANCER. 2010; 10: 116-29.
[12] Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther. 2010; 125: 105-17.
[13] Fibroblast growth factors and their receptors in cancer.
[14] Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. PHARMACOL THERAPEUT. 2010; 125: 105-17.
[15] Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. NAT REV CANCER. 2010; 10: 116-29.
[16] Kakiuchi-Kiyota S, Lappin PB, Heintz C, et al. Expression of proto-oncogene cFMS protein in lung, breast, and ovarian cancers. Appl Immunohistochem Mol Morphol. 2014; 22: 188-99.
[17] Ashton S, Song YH, Nolan J, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. SCI TRANSL MED. 2016; 8: 317r-325r.
[18] Wang C, Chen J, Cao W, Sun L, Sun H, Liu Y. Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways. EUR J PHARMACOL. 2016; 779: 1-7.
[19] Ambrogio C, Gómez-López G, Falcone M, et al. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. NAT MED. 2016; 22: 270-7.
[20] Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCI. 2018; 109: 1207-19.
[21] Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proceedings of the National Academy of Sciences. 2013; 110: 14711-6.
[22] Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). BRIT J CANCER. 2018; 118: 654-61.
[23] Ruan X, Shi X, Dong Q, et al. Antitumor effects of anlotinib in thyroid cancer. ENDOCR-RELAT CANCER. 2019: 153-64.
[24] He C, Wu T, Hao Y. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. BIOCHEM BIOPH RES CO. 2018; 503: 3093-9.
[25] Liang L, Hui K, Hu C, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J EXP CLIN CANC RES. 2019; 38.
[26] Wang G, Sun M, Jiang Y, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasisvia dual blockade of VEGFR2 and MET in osteosarcoma. INT J CANCER. 2019; 145: 979-93.
[27] Ahlin C, Lundgren C, Embretsén-Varro E, Jirström K, Blomqvist C, Fjällskog ML. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. BREAST CANCER RES TR. 2017; 164: 667-78.
[28] Ruan X, Shi X, Dong Q, et al. Antitumor effects of anlotinib in thyroid cancer. ENDOCR-RELAT CANCER. 2019: 153-64.
[29] Ravanan P, Srikumar IF, Talwar P. Autophagy: The spotlight for cellular stress responses. LIFE SCI. 2017; 188: 53-67.
[30] Matsuura K, Canfield K, Feng W, Kurokawa M. Metabolic Regulation of Apoptosis in Cancer. INT REV CEL MOL BIO. 2016; 327: 43-87.
[31] Sun Y, Du F, Gao M, et al. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer. THYROID. 2018; 28: 1455-61.
[32] Song S, Tan J, Miao Y, Li M, Zhang Q. Crosstalk of autophagy and apoptosis: Involvement of the dual role of autophagy under ER stress. J CELL PHYSIOL. 2017; 232: 2977-84.
[33] Heras-Sandoval D, Pérez-Rojas JM, Hernández-Damián J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. CELL SIGNAL. 2014; 26: 2694-701.
[34] Zhang W, Hou J, Yan X, et al. Platycodon grandiflorum Saponins Ameliorate Cisplatin-Induced Acute Nephrotoxicity through the NF-κB-Mediated Inflammation and PI3K/Akt/Apoptosis Signaling Pathways. NUTRIENTS. 2018; 10: 1328.
[35] Yu Y, Lv F, Liang D, et al. HOTAIR may regulate proliferation, apoptosis, migration and invasion of MCF-7 cells through regulating the P53/Akt/JNK signaling pathway. BIOMED PHARMACOTHER. 2017; 90: 555-61.